Health Canada has approved bepirovirsen, a new injectable treatment offering a potential “functional cure” for chronic hepatitis B, a viral infection affecting 260,000 Canadians.
While the drug clears viral markers in some patients, experts say cost, patient eligibility, and long-term durability must be addressed before it becomes a standard clinical option.
The approval, announced in early November, changes how clinicians manage a condition that has long relied on daily antiviral therapy to suppress the virus rather than eliminate it. CBC News reported that while the treatment offers hope for patients looking to discontinue long-term medication, hepatologists caution that the drug is not a universal solution for all those living with the infection.
Clinical Realities of the New Treatment
Chronic hepatitis B is characterized by the persistent presence of the virus in the liver, which can progress to cirrhosis—permanent scarring—or hepatocellular carcinoma, a type of liver cancer. Until now, standard care has involved nucleoside or nucleotide analogues, which prevent the virus from replicating but rarely clear the infection entirely.
Beprovirsen functions differently as an antisense oligonucleotide. By binding to specific RNA sequences of the virus, the drug triggers the degradation of viral messenger RNA, effectively reducing the levels of hepatitis B surface antigen (HBsAg) in the blood. “This new treatment, it completely clears all the viral markers for hepatitis B out of the blood,” Dr. Curtis Cooper, who leads the Ottawa Hospital’s viral hepatitis program, told CBC News.
How Bepirovirsen Provides a Functional Cure and Its Limitations
- Functional Cure: This does not mean the virus is eradicated from the body, but that viral levels drop low enough that the immune system can keep the infection in check without further daily medication.
- Targeted Eligibility: The treatment is not for everyone; specifically, patients with existing cirrhosis are currently excluded from the therapy due to clinical safety parameters.
- Injection vs. Pill: Unlike current treatments that involve a daily oral antiviral, bepirovirsen is administered via a series of injections, which may carry a higher risk of localized side effects like rashes.
Clinical Trial Results Show Viral Suppression and Uncertain Costs
Clinical trial data presented to regulators showed that approximately one-fifth of patients maintained undetectable viral levels 24 weeks after completing the treatment course.
“From the data that we have now, if it works, then we can reassure [patients] that they have a functional cure and they won't need to take any further hepatitis B treatments in the future,” Dr. Carla Coffin, a hepatologist and professor at the University of Calgary's Cumming School of Medicine, told CBC News.
The financial landscape for the drug remains uncertain. Dr. Eric Yoshida, a professor of medicine in the division of gastroenterology at the University of British Columbia, highlighted that in jurisdictions like Japan, the therapy costs approximately $84,000 Cdn. This pricing suggests that access may be restricted by provincial drug formularies and private insurance coverage, potentially limiting the drug’s reach to a small fraction of the patient population.
| Metric | Current Standard (Antivirals) | New Therapy (Bepirovirsen) |
|---|---|---|
| Administration | Daily Oral Pill | Course of Injections |
| Goal | Viral Suppression | Functional Cure |
| Primary Limitation | Life-long adherence required | High cost; limited to specific patients |
Who Should Avoid Bepirovirsen and Maintain Current Therapy
Patients currently managing chronic hepatitis B should not discontinue their existing antiviral therapy without direct supervision from a hepatologist or infectious disease specialist. Bepirovirsen is not indicated for patients with advanced liver disease, such as cirrhosis, where the liver’s ability to process medications and recover is already compromised.
Beyond new pharmaceuticals, public health experts continue to emphasize the role of vaccination. While Canada recently moved to recommend universal infant immunization, global efforts remain uneven. According to World Health Organization data, 75 percent of hepatitis B-related deaths in 2024 occurred in the African and Western Pacific regions, showing that while medical breakthroughs provide individual hope, systemic prevention remains the primary tool for global eradication.
“We still have a long way to go,” Dr. Carla Coffin, a hepatologist and professor at the University of Calgary's Cumming School of Medicine, said.
